Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of urinary CA19-9 levels in bladder cancer patients classified according to the combinations of Lewis and Secretor blood group genotypes.

International journal of urology : official journal of the Japanese Urological Association - 1 Sept 2007

Nagao Keiji, Itoh Yukio, Fujita Kazuhiko, Fujime Makoto

Abstract excerpt

OBJECTIVES: This study evaluated the clinical significance of urinary CA19-9 levels in bladder cancer patients classified according to various combinations of Lewis (Le) and Secretor (Se) genotypes. METHODS: Urinary CA19-9 and DU-PAN-2 levels were measured as units per mg creatinine (U/mg Cr) in 121 patients with bladder cancer and in 31 patients with other urologic diseases. Genotyping was carried out using...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Alleles

Share to Antigens, Neoplasm

Share to CA-19-9 Antigen

Share to Case-Control Studies

Share to Genotype

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 17760744
DOI: 10.1111/j.1442-2042.2007.01840.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of urinary CA19-9 levels in bladder cancer patients classified according to the combinations of Lewis and Secretor blood group genotypes.PMID 17760744Read ↗

Increased concentrations of genotype-interpreted Ca 19-9 in urine of bladder cancer patients mark diffuse atypia of the urothelium.Semantic proximity Read ↗

Smoking and serum CA19-9 levels according to Lewis and secretor genotypes.Semantic proximity Read ↗

Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping.Semantic proximity Read ↗

Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients.Semantic proximity Read ↗

Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population.Semantic proximity Read ↗

The relationship between Lewis/Secretor genotypes and serum carbohydrate antigen 19-9 levels in a Korean population.Semantic proximity Read ↗

New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer.Semantic proximity Read ↗

Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer.Semantic proximity Read ↗

Investigation of unexpected serum CA19-9 elevation in Lewis-negative cancer patients.Semantic proximity Read ↗

CA19-9-Low&Lewis (+) pancreatic cancer: A unique subtype.Semantic proximity Read ↗

Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype.Semantic proximity Read ↗

Elevated serum CA19-9 levels in poorly controlled diabetic patients. Relationship with Lewis blood group.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.